Costs of HIV+/AIDS at CD4+ counts disease stages based on treatment protocols

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 4, 1996, Pages 413-420

  Gable, Carol B ^a   Tierce, Jonothan C ^b   Simison, Diane ^a   Ward, Douglas ^c   Motte, Katy ^a,d   Dodson, Ann ^a  

^a State and Federal Associates   (United States)

^b Churchill Communications   (United States)

^c State and Federal Associates Inc ^*

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CD4+ counts; Costs; HIV+ AIDS; Opportunistic diseases; Treatment protocols

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL PROTOCOL; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH SERVICE; HOSPITAL PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; OPPORTUNISTIC INFECTION; OUTPATIENT; PATIENT CARE; PRIORITY JOURNAL; TREATMENT PLANNING;

CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM COMPLEX; PNEUMOCYSTIS CARINII;

EID: 0029788146     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199608010-00013     Document Type: Article

References (47)

1. Centers for Disease Control, HIV/AIDS Surveillance Report. No. 7 USDHHS, Atlanta: CDC, 1995.
2. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-9.
3. Graham NM, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992;326:1037-42.
4. Lemp GF, Payne SF, Neal D, et al. Survival trends for patients with AIDS. JAMA 1990;263:402-6.
5. Hay JW, Osmond DH, Jacobson MA. Projecting the medical costs of AIDS and ARC in the United States. J Acquir Immune Defic Syndr 1988;1:466-85.
6. Hellinger FJ. Forecasts of the costs of medical care for persons with HIV: 1992-1995. Inquiry 1992;29:356-65.
7. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993;270:474-8.
8. Hellinger FJ, Fleishman JA, Hsia DC. AIDS treatment cost during the last month of life: evidence from the ACSUS. Health Serv Res 1994;29:569-81.
9. Green J, Oppenheimer GM, Wintfeld N. The $147,000 misunderstanding: repercussions of overestimating the cost of AIDS. J Health Polit Policy Law 1994.;19:69-90.
10. Hoover DR, Taylor JM, Black CA, et al. The effect of changing the definition of AIDS on the modeling of AIDS. JAMA 1992;267:2737-8.
11. Paltiel AD, Kaplan EH. Modeling zidovudine therapy: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1991;4:795-804.
12. Piette JD, Intrator O, Zierler S, Mor V, Stein MD. An exploratory analysis of survival with AIDS using a nonparametric tree-structured approach. Epidemiology 1992;3: 310-8.
13. Bozzette SA, Parker R, Hay J. A cost analysis of approved antiretroviral strategies in persons with advanced human immunodeficiency virus disease and zidovudine intolerance. J AIDS Hum Retrovirol 1994;7:355-62.
14. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA 1991;266:820-4.
15. 3: a costeffectiveness analysis. J Acquir Immune Defic Syndr 1991; 4:521-31.
16. Freedberg KA. Clinical and economic aspects of prophylaxis and treatment of Pneumocystis carinii pneumonia. Pharmacoeconomics 1995;7:95-8.
17. Lynn LA, Schulman KA, Eisenberg JM. The pharmacoeconomics of HIV disease. Pharmacoeconomics 1992;1:161-74.
18. Moore RD, Hidalgo J, Bareta JC, Chaisson RE. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immune Defic Syndr 1994;7:349-54.
19. Rietmeijer CA, Davidson AJ, Foster CT, et al. Cost of care for patients with human immunodeficiency virus infection. Arch Intern Med 1993;153:219-25.
20. Wachter RM, Luce JM, Safrin S, Berrios DC, Charlebois E, Scitovsky AA. Cost and outcome of intensive care for patients with AIDS, Pneumocystis carinii pneumonia, and severe respiratory failure. JAMA 1995;273:230-5.
21. Crowe SM, Carlin JB, Steward KI, et al. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770-6.
22. Munoz A, Schrager LK, Bacellar H, et al. Trends in the incidence of AIDS-defining outcomes in the multicenter AIDS cohort study, 1985-1991. In: Nicolosi A, HIV epidemiology: models and methods. New York: Raven Press, 1994:255-78.
23. Brundage JF, McNeil JG, Miller RN, et al. The current distribution of CD4+ T-lymphocytes counts among adults in the United States with human immunodeficiency virus infections: estimates based on the experience of the U.S. Army. J Acquir Immune Defic Syndr 1990;3:92-4.
24. Physicians' Desk Reference. Montvale, NJ: Medical Economics Data Production Company, 1995.
25. Bureau of Labor Statistics. Consumer Price Index. Washington, D.C: U.S. Department of Labor. 1994.
26. McNeil JG, Brundage JF, Wann F, et al. Direct measurement of human immunodeficiency virus seroconversions in a serially tested population of young adults in the United States Army, October 1985 to October 1987. N Engl J Med 1989;320:1581-5.
27. U.S. Department of Health and Human Services. Quick reference guide for clinician's managing early HIV infection. Rockville, MD: Agency for Healthcare Policy and Research, Publication no. 94-0573, January 1994.
28. U.S. Department of Health and Human Services. Evaluation and management of early HIV infection. Rockville, MD: Agency for Healthcare Policy and Research, Publication no. 94-0572, January 1994.
29. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR 1989;38(suppl 5):1-9.
30. Advisory Committee for the Elimination of Tuberculosis (ACET). Recommendation on tuberculosis and human immunodeficiency virus infection. MMWR 1989;38:236-8, 243-50.
31. O'Brien R. The diagnosis, treatment and prevention of tuberculosis in patients with HIV. PAAC NOTES 1992;4:179-81.
32. U.S. Department of Health and Human Services Public Health Service. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. MMWR 1993;42(RR-9):14-20.
33. Public Health Service Task Force on Antipneumocystis Prophylaxis for Patients with Human Immunodeficiency Virus Infection. Recommendation for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR 1992;41(RR-4):1-11.
34. Centers for Disease Control. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR 1991;40(RR-5):27-32.
35. Centers for Disease Control. The use of preventive therapy for tuberculosis infection in the United States: recommendations of the advisory committee for elimination of tuberculosis. MMWR 1990;39(RR-8):9-12.
36. Broder S, Mitsuya H, Yarchoan R, Pavlakis GN. NIH Conference. Antiretroviral therapy in AIDS. Ann Intern Med 1990;113:604-18.
37. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317: 185-91.
38. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990;112:727-37.
39. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992;326:437-43.
40. Lambert JS, Seidlin M, Reichman RC, et al. 2′,3′-Dideoxymosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. N Engl J Med 1990;322:1333-9.
41. Meng TC, Fischl MA, Boota AM, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med 1992;116:13-20.
42. Merigan TC. Treatment of AIDS with combinations of antiretroviral agents. Am J Med 1991;90(suppl 4A):8S-17S.
43. Skowron G, Bozzette SA, Lim L, et al. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med 1993;118:321-30.
44. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990;322:941-9.
45. + T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach. J Acquir Immune Defic Syndr 1991;4:1141-7.
46. + count to survival in patients with human immunodeficiency virus infection. Arch Intern Med 1993;153:1313-8.
47. + lymphocyte counts to survival in a cohort of hemophiliacs infected with HIV. J AIDS Hum Retrovirol 1994;7:1095-8.